Ocular Therapeutix Stock Price and Value Analysis

Ocular Therapeutix (NasdaqGM:OCUL) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Ocular Therapeutix to reach your target.

Target type

OCUL Free Cash Flow Trend

Free Cash Flow trendline for OCUL
Free Cash Flow trendline for Ocular Therapeutix

Hmm, we can't give any reliable projection for Ocular Therapeutix's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the OCUL Numbers

OCUL Price
(Ocular Therapeutix stock price per share)
$5.57
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 43%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Ocular Therapeutix's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2020-01-02 Opaleye Management Inc. Buy 15,000 $3.90
2019-12-30 Opaleye Management Inc. Buy 15,000 $3.97
2019-12-30 Opaleye Management Inc. Buy 5,000 $3.97

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 28,998,345 shares shorted. With 182,975,394 shares available for purchase and an average trading volume over the past 10 trading days of 3,245,850, it would take at least 8.9 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Net income was negative in all 14 fiscal years from 2012 to 2025, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$879 million over those years, against net income of -$1,124 million.

In 2025, net income was -$266 million and operating cash flow was -$205 million, so no ratio is shown for that year.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2012 -14.1 -12.6 0.2 n/a
2013 -13.3 -12.6 0.4 n/a
2014 -28.6 -20.5 1.3 n/a
2015 -39.7 -33.7 1.8 n/a
2016 -44.7 -34 1.9 n/a
2017 -63.4 -50.5 8.3 n/a
2018 -60 -49.2 1.9 n/a
2019 -86.4 -77.6 2.2 n/a
2020 -156 -53.6 0.8 n/a
2021 -6.6 -65.5 1.2 n/a
2022 -71 -59.6 3.7 n/a
2023 -80.7 -70.2 6.1 n/a
2024 -194 -135 1.3 n/a
2025 -266 -205 12 n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $0 million in 2012 and $52 million in 2025, a compound annual growth rate of 93.1% over 13 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue fell 18.5% from 2024 to 2025.

Our estimated free cash flow was -$210 million in 2025, a negative margin of 403.7% of revenue, meaning the estimate was below zero. In 2012 the estimated margin was negative 127880.0%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2012 0 -12.8 -127880.0%
2014 0.8 -21.1 -2734.8%
2015 1.8 -34.6 -1980.0%
2016 1.9 -35.1 -1860.6%
2017 1.9 -53.2 -2766.1%
2018 2 -52.2 -2625.5%
2019 4.2 -80.8 -1911.4%
2020 17.4 -56.6 -325.1%
2021 43.5 -68.4 -157.2%
2022 51.5 -61.6 -119.6%
2023 58.4 -73 -125.0%
2024 63.7 -137 -215.5%
2025 52 -210 -403.7%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $737 million against total liabilities of $154 million, or 479.4% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 19.0% of total assets in 2025, compared with 410.6% in 2013, a decrease of 391.6 percentage points.

Stockholders equity was $654 million in 2025, up from negative equity of -$59.5 million in 2013.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2013 19.1 17.5 78.6 -59.5
2014 78.2 37.4 19.5 58.7
2015 110 30.8 20.7 89.6
2016 74.9 32.9 22.9 52
2017 55.4 41.5 29.3 26.1
2018 73 54.1 37.2 35.9
2019 78.7 54.4 82.4 -3.6
2020 262 228 186 76.1
2021 205 164 117 88
2022 149 102 114 35.4
2023 252 196 161 91.1
2024 458 392 143 315
2025 808 737 154 654

Price Versus Our Estimated Value

None of the 14 fiscal years we have for Ocular Therapeutix under its current SEC filer shows positive free cash flow.

We do not estimate a fair value for Ocular Therapeutix while its free cash flow growth is not positive, so there is no value comparison here.

Year-to-year variability in free cash flow is volatile, measured at 43%.

We do not have a dividend yield for Ocular Therapeutix.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Ocular Therapeutix, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Ocular Therapeutix (OCUL) 1,226 - - - -
Amphastar Pharmaceuticals (AMPH) 1,205 13.0 - 0.9% 98% above
Innoviva (INVA) 1,309 7.8 - - 12% above
Phibro Animal Health Corporation (PAHC) 1,352 13.9 1.4% - 82% above
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
Collegium Pharmaceutical (COLL) 768 22.7 - - 155% above
Perrigo Company plc (PRGO) 2,213 - 7.2% 72.9% 91% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1393434.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 14 of the 14 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: OCUL annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in OCUL

Does Ocular Therapeutix have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: OCUL

This example shows how we apply the Trendshare checklist to OCUL: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 5.57
    • Market cap: $1.2B
    • EPS: -1.44
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.